Movatterモバイル変換

[0]ホーム
URL:

ECSP10010551A - MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME - Google Patents

MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Info

Publication number
ECSP10010551A
ECSP10010551AEC2010010551AECSP10010551AECSP10010551AEC SP10010551 AECSP10010551 AEC SP10010551AEC 2010010551 AEC2010010551 AEC 2010010551AEC SP10010551 AECSP10010551 AEC SP10010551AEC SP10010551 AECSP10010551 AEC SP10010551A
Authority
EC
Ecuador
Prior art keywords
factor
modified
polypeptides
polipeptides
same
Prior art date
Application number
EC2010010551A
Other languages
Spanish (es)
Inventor
John E Murphy
Alan Brooks
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Healthcare Llc
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Bayer Schering Pharma AgfiledCriticalBayer Healthcare Llc
Publication of ECSP10010551ApublicationCriticalpatent/ECSP10010551A/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

Se divulgan polipeptidos modificados del factor IX, tales como los polipeptidos del factor IX con uno o mas sitios de glicosilacion introducidos. Los polipeptidos modificados del factor IX pueden exhibir un incremento de la estabilidad in vitro o in vivo, tal como una semivida plasmatica mas prolongada. Asimismo se divulgan procedimientos de fabricar polipeptidos modificados del factor IX y a procedimientos de usar modificados del factor IX para, por ejemplo, tratar a pacientes afectados por hemofilia B.Modified factor IX polypeptides, such as factor IX polypeptides with one or more glycosylation sites introduced are disclosed. Modified factor IX polypeptides may exhibit increased stability in vitro or in vivo, such as a longer plasma half-life. Methods of manufacturing modified factor IX polypeptides and methods of using modified factor IX are also disclosed to, for example, treat patients affected by hemophilia B.

EC2010010551A2008-04-162010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAMEECSP10010551A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US12456708P2008-04-162008-04-16
US4596108P2008-04-172008-04-17

Publications (1)

Publication NumberPublication Date
ECSP10010551Atrue ECSP10010551A (en)2010-11-30

Family

ID=41265284

Family Applications (1)

Application NumberTitlePriority DateFiling Date
EC2010010551AECSP10010551A (en)2008-04-162010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Country Status (17)

CountryLink
EP (1)EP2288622A4 (en)
JP (1)JP2011517951A (en)
KR (1)KR20110005862A (en)
CN (1)CN102083856A (en)
AU (1)AU2009244633A1 (en)
BR (1)BRPI0910702A2 (en)
CA (1)CA2721683A1 (en)
CO (1)CO6311000A2 (en)
CR (1)CR11737A (en)
DO (1)DOP2010000311A (en)
EC (1)ECSP10010551A (en)
IL (1)IL208718A0 (en)
MX (1)MX2010011345A (en)
RU (1)RU2010146387A (en)
SG (1)SG189790A1 (en)
SV (1)SV2010003704A (en)
WO (1)WO2009137254A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP2423305A1 (en)*2006-06-192012-02-29Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatment
JP5613876B2 (en)*2007-10-152014-10-29ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Human factor IX variants with extended half-life
ES2940323T3 (en)2008-09-152023-05-05Uniqure Biopharma B V Factor IX polypeptide mutant, its uses and a method for its production
KR20220097518A (en)2010-07-092022-07-07바이오버라티브 테라퓨틱스 인크.Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en)*2010-11-032016-03-17Gc Biopharma Corp.Modified factor ix polypeptides and uses thereof
TWI595004B (en)*2010-11-032017-08-11介控生化科技公司 Modified ninth factor multi-peptide and use thereof
US9486507B2 (en)2011-06-102016-11-08Biogen Ma Inc.Pro-coagulant compounds and methods of use thereof
US10656167B2 (en)2011-07-252020-05-19Bioverativ Therapeutics Inc.Assays to monitor bleeding disorders
JP5967631B2 (en)*2012-04-272016-08-10学校法人日本大学 Treatment for epithelial and endothelial damage
WO2014018777A2 (en)2012-07-252014-01-30Biogen Idec Ma Inc.Blood factor monitoring assay and uses thereof
HK1213521A1 (en)2012-09-252016-07-08Bioverativ Therapeutics Inc.Methods of using fix polypeptides
US10391152B2 (en)2012-10-182019-08-27Bioverativ Therapeutics Inc.Methods of using a fixed dose of a clotting factor
US10717965B2 (en)2013-01-102020-07-21Gloriana Therapeutics, Inc.Mammalian cell culture-produced neublastin antibodies
FI2956477T4 (en)2013-02-152024-04-24Bioverativ Therapeutics IncOptimized factor viii gene
JP6387392B2 (en)2013-03-152018-09-05バイオベラティブ セラピューティクス インコーポレイテッド Factor IX polypeptide preparation
WO2015048330A2 (en)2013-09-252015-04-02Biogen Idec Ma Inc.On-column viral inactivation methods
US10584147B2 (en)2013-11-082020-03-10Biovertiv Therapeutics Inc.Procoagulant fusion compound
WO2015085276A1 (en)2013-12-062015-06-11Biogen Idec Ma Inc.Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en)2013-12-202015-06-25Biogen Idec Ma Inc.Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
AU2015236340B2 (en)2014-03-242020-02-06Bioverativ Therapeutics Inc.Lyophilized factor IX formulations
WO2016004113A1 (en)2014-06-302016-01-07Biogen Ma Inc.Optimized factor ix gene
GB201420139D0 (en)2014-11-122014-12-24Ucl Business PlcFactor IX gene therapy
CA2994547A1 (en)2015-08-032017-02-09Bioverativ Therapeutics Inc.Factor ix fusion proteins and methods of making and using same
SI3411478T1 (en)2016-02-012022-10-28Bioverativ Therapeutics Inc. Optimized factor VIII genes
CN105695616A (en)*2016-04-222016-06-22王冬国Analysis marker for diagnosing thyroid cancer and application thereof
BR112019011115A2 (en)2016-12-022019-10-01Bioverativ Therapeutics Inc methods for treating hemophilic arthropathy using chimeric clotting factors
WO2018144623A1 (en)2017-01-312018-08-09Bioverativ Therapeutics Inc.Factor ix fusion proteins and methods of making and using same
FR3069540B1 (en)2017-07-282019-09-13Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
MX2020001593A (en)2017-08-092020-07-13Bioverativ Therapeutics Inc NUCLEIC ACID MOLECULES AND USES THEREOF.
KR20200057051A (en)2017-09-272020-05-25시질론 테라퓨틱스, 인크. Methods, compositions and implantable elements comprising active cells
US11491212B1 (en)2017-09-272022-11-08Catalyst Biosciences, Inc.Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
JP7534219B2 (en)2018-04-042024-08-14シギロン セラピューティクス， インコーポレイテッド Implantable particles and related methods
WO2019195056A1 (en)2018-04-042019-10-10Sigilon Therapeutics, Inc.Methods, compositions, and implantable elements comprising stem cells
DK3793588T3 (en)2018-05-182025-06-16Bioverativ Therapeutics Inc METHODS FOR TREATING HEMOPHILIA A
MX2021001599A (en)2018-08-092021-07-02Bioverativ Therapeutics IncNucleic acid molecules and uses thereof for non-viral gene therapy.
GB201813528D0 (en)2018-08-202018-10-03Ucl Business PlcFactor IX encoding nucleotides
US10842885B2 (en)2018-08-202020-11-24Ucl Business LtdFactor IX encoding nucleotides
UY38389A (en)2018-09-272020-04-30Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en)2018-10-262020-04-30The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesA high-yield perfusion-based transient gene expression bioprocess
WO2020215010A1 (en)2019-04-172020-10-22Codiak Biosciences, Inc.Compositions of exosomes and aav
EP4038182A1 (en)2019-09-302022-08-10Bioverativ Therapeutics Inc.Lentiviral vector formulations
WO2021154414A2 (en)2020-01-292021-08-05Catalyst Biosciences, Inc.Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
KR20230074703A (en)2020-06-242023-05-31바이오버라티브 테라퓨틱스 인크. Method for removing free factor VIII from preparations of lentiviral vectors modified to express the protein
AU2022226969A1 (en)2021-02-242023-09-14Bluehalo LlcSystem and method for a digitally beamformed phased array feed
CN120659872A (en)2022-10-112025-09-16西吉隆医疗股份有限公司 Engineered cells and implantable devices for treating disease
WO2024081309A1 (en)2022-10-112024-04-18Sigilon Therapeutics, Inc.Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FR2638643B1 (en)*1988-11-091991-04-12Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en)*1997-07-211999-01-28The University Of North Carolina At Chapel HillFactor ix antihemophilic factor with increased clotting activity
PL369065A1 (en)*2001-09-042005-04-18Merck Patent GmbhModified factor ix
KR20060034216A (en)*2003-04-092006-04-21넥타르 테라퓨틱스 Hemophilia Treatment by Inhalation of Coagulation Factors
US20060040856A1 (en)*2003-12-032006-02-23Neose Technologies, Inc.Glycopegylated factor IX
WO2005055950A2 (en)*2003-12-032005-06-23Neose Technologies, Inc.Glycopegylated factor ix
EP2423305A1 (en)*2006-06-192012-02-29Catalyst Biosciences, Inc.Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en)*2007-01-092010-04-20Shu-Wha LinRecombinant human factor IX and use thereof

Also Published As

Publication numberPublication date
SV2010003704A (en)2011-02-21
WO2009137254A2 (en)2009-11-12
BRPI0910702A2 (en)2016-07-05
SG189790A1 (en)2013-05-31
MX2010011345A (en)2011-02-23
WO2009137254A3 (en)2010-01-14
IL208718A0 (en)2010-12-30
EP2288622A2 (en)2011-03-02
CR11737A (en)2011-02-07
JP2011517951A (en)2011-06-23
RU2010146387A (en)2012-05-27
KR20110005862A (en)2011-01-19
EP2288622A4 (en)2012-04-18
CN102083856A (en)2011-06-01
CA2721683A1 (en)2009-11-12
DOP2010000311A (en)2011-02-28
AU2009244633A1 (en)2009-11-12
CO6311000A2 (en)2011-08-22

Similar Documents

PublicationPublication DateTitle
ECSP10010551A (en) MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME
CR20120052A (en) MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME
ECSP12011908A (en) OCTAHIDROPIRROLO [3,4-c] PIRROLOS DISUSTITUIDOS AS
DOP2016000042A (en) ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME
CO6331368A2 (en) MODIFIED POLIPEPTIDE FACTORS VII (FVII)
IN2014DN09782A (en)
BRPI0920914A8 (en) ALPHA-KETO PERACIDS AND METHODS FOR PRODUCING AND USING THEM.
SV2009003393A (en) FACTOR POLIPEPTIDES VII MODIFICATIONS AND USES OF THE SAME
AR084057A1 (en) COMPOSITIONS FOR FABRIC CARE
CR11520A (en) VIRUELA ONCOLITIC VIRUS VECTORS
MX354698B (en) SUPPLY PARTICLE.
GT201500069A (en) NEW BICYCLIC PYRIDINONES
GT200900309A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
DOP2010000251A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
DOP2012000170A (en) PROCESS FOR THE MANUFACTURE OF AN ACTIVE PHARMACEUTICALLY AGENT
PA8796001A1 (en) HISTAMINE H4-FURO-PYRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER
UY32444A (en) COMPOSITIONS AND PROCEDURES FOR EXTENDED THERAPY WITH AMINOPIRIDINS
CL2020000019A1 (en) Iiarn agents for the inhibition of alpha-enac expression and methods of use.
MX2012001409A (en)Modified agrin-fragment capable of restoring muscle strength for use as a medicament.
UY29250A1 (en) CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANES MODIFIED IN C-2.-
UY32975A (en) AMINOPIRIDINE DERIVATIVES
ECSP13012613A (en) METHOD FOR PRODUCING AND USING A SOUND CARBOXIMETILCELLULOSE AND GOSIPOL COPOLYMER
UY29371A1 (en) PIRROLES REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCESS
CR11457A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HIALURONIC ACID AND USES OF THE SAME
[8]ページ先頭
©2009-2025 Movatter.jp